Skip to main content
Clinical Trials/NCT03035929
NCT03035929CompletedPhase 1

Diagnosing Natriuretic Peptide Deficiency: A Pilot Study

Vanderbilt University Medical Center1 site in 1 country10 target enrollmentStarted: January 1, 2017Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
10
Locations
1
Primary Endpoint
Changes in NT-proANP From Baseline to 8 Hours

Study Overview

Brief Summary

In this pilot study, the investigators will determine the response of the natriuretic peptide (NP) hormone system after a dose of intravenous dexamethasone (a steroid medication). The goal of the proposed project is to generate preliminary data that will be used to develop power calculations, inform cutoff ranges, and inform the timing of the NP response for larger subsequent studies.

Aim: To determine the range of distribution and time course of natriuretic peptide (NP) responses to a single dose of dexamethasone IV 4 mg in healthy lean individuals.

Hypothesis: Determination of the NP responses (the range and time course of changes in NP levels) to dexamethasone in 10 healthy individuals will inform the time course and frequency of blood sampling in a definitive prospective study, as well as enable investigators to perform a sample size calculation for a definitive prospective study.

Detailed Description

see above

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Significant use of systemically-absorbed glucocorticoids currently or for an extended period of time during the prior 6 months
  • Current use of antihypertensive medications
  • Current use of metformin, or any antidiabetic medications (which could affect glucose and insulin levels)
  • Current use of medications known to affect dexamethasone metabolism, including phenytoin, rifampin, carbamazepine, troglitazone, and barbiturates
  • Active, clinically significant infection at time of visit
  • History of adrenal insufficiency or Cushing's syndrome
  • Prior or current cardiovascular disease, renal disease, or liver disease
  • Diabetes mellitus, pre-diabetes, impaired fasting glucose, or impaired glucose tolerance
  • Atrial fibrillation
  • Bleeding disorder or anemia
  • Elevated Liver Functions Tests > 2 times upper limit of normal
  • Estimated glomerular filtration rate < 60 ml/min
  • HbA1c > 5.7
  • Abnormal sodium or potassium level
  • Positive pregnancy test, women of child-bearing age not practicing birth control, women who are breastfeeding

Arms & Interventions

Healthy

Experimental

10 Healthy subjects will undergo study procedures at four study visits.

All subjects will undergo the same procedures and interventions.

Intervention: Dexamethasone (Drug)

Outcomes

Primary Outcomes

Changes in NT-proANP From Baseline to 8 Hours

Time Frame: baseline and 8 hours

Change in natriuretic peptide levels after drug administration

Changes in NT-proBNP From Baseline to 8 Hours

Time Frame: Baseline and 8 hours

Change in natriuretic peptide levels after drug administration

Secondary Outcomes

  • Changes in NT-proANP(baseline, 24 hours, 48 hours and 72 hours)
  • Changes in NT-proBNP(at baseline, 24 hours, 48 hours and 72 hours)
  • BNP (B-type Natriuretic Peptide)(0-8 hrs, 24 hrs, 48 hrs, 72 hrs after drug administration)
  • ANP (Atrial Natriuretic Peptide)(0-8 hrs, 24 hrs, 48 hrs, 72 hrs after drug administration)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Katherine N. Bachmann, MD

Instructor in Medicine

Vanderbilt University Medical Center

Study Sites (1)

Loading locations...

Similar Trials